Advertisement
ALGN vs DXCM
Which Stock Would AI Choose? Align Technology (ALGN) vs. DexCom (DXCM) Stock Comparison
Key Takeaways
- DXCM is delivering double-digit revenue growth and rising guidance, while ALGN is growing in the low single digits and recently trimmed its full-year revenue outlook.
- Both companies are profitable medical device leaders, but DXCM enjoys stronger near-term momentum, with shares up roughly 25% year to date versus a more mixed trajectory for ALGN.
- Tickeron AI Verdict: Based on trend consistency, growth, and catalyst strength, Tickeron's AI currently favors DXCM over ALGN.
- For more detail on each name, explore ALGN Major News, ALGN Today's Price Move, DXCM Major News, and DXCM Today's Price Move.
- To see which AI-driven strategies are currently the best fit for the market, visit the curated Trending AI Robots page.
Introduction
Investors evaluating healthcare innovation often weigh ALGN (Align Technology) against DXCM (DexCom) because both occupy leadership positions in specialized, fast-evolving corners of medical technology. Align dominates clear aligners through its Invisalign system and iTero scanners, while DexCom is a leader in continuous glucose monitoring (CGM) devices for diabetes and metabolic health. Although both are categorized as medical device companies, they face different demand drivers, reimbursement dynamics, and growth trajectories. This stock comparison examines recent relative performance, business fundamentals, and market positioning to help traders and investors assess which name currently presents the more compelling risk-reward profile.
ALGN Overview and Recent Performance
ALGN is the global leader in clear aligners, selling its Invisalign system alongside iTero intraoral scanners and exocad software for digital orthodontics. In recent market activity, the stock has traded well below its 52-week high, reflecting investor caution around slowing growth and a softer consumer environment. Align's most recent quarter showed roughly 2% revenue growth, with clear aligner shipments rising in the mid-single digits while its imaging systems and CAD/CAM (computer-aided design and manufacturing) segment posted a revenue decline driven by a shift toward lower-priced scanners and flexible purchasing models.
Several developments have shaped sentiment in recent weeks. The company lowered its full-year revenue guidance and announced a leadership transition, with Jennifer Davis set to succeed Joseph Hogan as chief executive at year-end. Management also cited a broadly cautious consumer as a headwind. On the positive side, Align announced a $270 million accelerated stock repurchase agreement, and the shares participated in a broader medical-device rally following recent U.S. midterm election results. Record doctor submissions and international shipment growth provide some offset, but competitive pressure in clear aligners and pricing questions remain central to the debate.
DXCM Overview and Recent Performance
DXCM is a leading developer of continuous glucose monitoring (CGM) systems used by people with diabetes, including an expanding base of type 2 patients who do not use insulin. The stock has been a standout performer, gaining roughly 25% or more year to date and outperforming both its industry and the broader market. In its most recent quarter, DexCom grew revenue about 11% year over year, with U.S. sales climbing roughly 14% on share gains and strong demand, while international growth moderated amid tougher comparisons from prior reimbursement wins.
Recent catalysts have reinforced momentum. DexCom's CONNECT trial, published in the New England Journal of Medicine, showed meaningful A1c (a measure of average blood sugar) improvement among non-insulin type 2 patients, supporting the case for broader reimbursement. The company is accelerating the rollout of its G7 15 Day sensor, raised full-year revenue and margin guidance, and authorized a new $1 billion share repurchase program. Gross margin expanded materially on manufacturing efficiencies. Risks include competition from Abbott and others, some international pricing pressure, and near-term costs tied to a new Ireland manufacturing facility.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of covered symbols. Because market conditions change constantly, not every bot is equally well-suited to the current environment — which is why only the strongest, most relevant strategies earn a place in the curated Trending AI Robots section. These highlighted bots span a range of approaches, from swing trading and trend following to shorter-horizon setups, and feature performance statistics designed to help traders identify options aligned with their objectives. Reviewing the page can provide a data-driven starting point for finding strategies that match today's conditions.
Head-to-Head Comparison
While both companies are healthcare innovators, their growth profiles diverge sharply. DXCM is compounding revenue at a low-teens rate with rising guidance and expanding margins, whereas ALGN is growing in the low single digits and recently reduced its outlook. DexCom's addressable market is widening through clinical validation and potential Medicare coverage for non-insulin type 2 patients; Align, by contrast, faces persistent consumer softness and intensifying competition in clear aligners.
On capital allocation, both returned cash to shareholders — Align through an accelerated repurchase and DexCom through a completed and renewed buyback. In terms of market positioning, DexCom currently exhibits stronger price momentum and clearer near-term catalysts, while Align is navigating a CEO transition and pricing questions in its systems business. Risk profiles also differ: DexCom contends with a dominant rival in Abbott and reimbursement timing, while Align faces competitive erosion and discretionary-spending sensitivity. On balance, DexCom's trend consistency and growth visibility present a more favorable relative setup in the current environment.
Tickeron AI Verdict
Weighing observable factors — revenue growth, guidance direction, margin expansion, catalyst quality, and trend consistency — Tickeron's AI would currently favor DXCM over ALGN. DexCom's stronger and more stable growth trajectory, upward revisions, and concrete clinical and reimbursement catalysts give it a probabilistic edge in relative positioning. Align remains a quality franchise with improving doctor engagement, but slower growth and a leadership transition introduce greater uncertainty. This assessment reflects relative momentum and fundamentals rather than a definitive prediction, and conditions can shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Buy and DXCM is a Buy.
ALGN in upward trend: price rose above 50-day moving average on November 02, 2026
ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 55 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 26 of 41 cases over the following month. The odds of a continued upward trend are 63%.
The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +1.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 190 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 153 of 206 cases where ALGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 16 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ALGN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ALGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.786) is normal, around the industry mean (4.964). P/E Ratio (28.769) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALGN | DXCM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 27 | |
PRICE GROWTH RATING 1..100 | 42 | 45 | |
P/E GROWTH RATING 1..100 | 33 | 53 | |
SEASONALITY SCORE 1..100 | n/a | 5 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (63) in the Medical Specialties industry is in the same range as DXCM (83). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that DXCM’s stock grew somewhat faster than ALGN’s over the last 12 months.
ALGN's Price Growth Rating (42) in the Medical Specialties industry is in the same range as DXCM (45). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
ALGN's P/E Growth Rating (33) in the Medical Specialties industry is in the same range as DXCM (53). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
| ALGN | DXCM | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 67% | 3 days ago 63% |
| Stochastic ODDS (%) | 3 days ago 81% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 69% | 3 days ago 70% |
| MACD ODDS (%) | 3 days ago 63% | 3 days ago 69% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 75% |
| Advances ODDS (%) | 11 days ago 70% | 7 days ago 67% |
| Declines ODDS (%) | 13 days ago 76% | 3 days ago 74% |
| BollingerBands ODDS (%) | 3 days ago 74% | 3 days ago 64% |
| Aroon ODDS (%) | 3 days ago 74% | 3 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green while DXCM’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 1 green, 4 red.
- DXCM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 6 TA indicator(s) are bullish while DXCM’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 6 bullish, 4 bearish.
- DXCM’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +10.75% price change this week, while DXCM (@Medical/Nursing Services) price change was -3.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.17%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +12.16%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
Reported Earning Dates
ALGN is expected to report earnings on Feb 03, 2027.
DXCM is expected to report earnings on Feb 11, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+2.17% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ALGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALGN has been closely correlated with NVST. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALGN jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | +4.16% | ||
| NVST - ALGN | 71% Closely correlated | +0.84% | ||
| XRAY - ALGN | 59% Loosely correlated | -6.24% | ||
| ICUI - ALGN | 53% Loosely correlated | +2.66% | ||
| LUNG - ALGN | 52% Loosely correlated | N/A | ||
| SOLV - ALGN | 50% Loosely correlated | +3.67% | ||
More | ||||
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -5.98% | ||
| ISRG - DXCM | 46% Loosely correlated | -3.36% | ||
| ALGN - DXCM | 44% Loosely correlated | +4.16% | ||
| LIVN - DXCM | 42% Loosely correlated | -1.26% | ||
| PODD - DXCM | 41% Loosely correlated | -6.16% | ||
| NVST - DXCM | 40% Loosely correlated | +0.84% | ||
More | ||||